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Abstract: Understanding the nanoscale structural changes can provide the physical state of 
cells/tissues. It has been now shown that increases in nanoscale structural alterations are 
associated with the progress of carcinogenesis in most of the cancer cases, including early 
carcinogenesis. Anti-cancerous therapies are intended for the growth inhibition of cancer cells; 
however, it is challenging to detect the efficacy of such drugs in early stages of treatment. A 
unique method to assess the impact of anti-cancerous drugs on cancerous cells/tissues is to probe 
the nanoscale structural alterations. In this paper, we study the effect of different anti-cancerous 
drugs on ovarian tumorigenic cells, using their nanoscale structural alterations as a biomarker. 
Transmission electron microscopy (TEM) imaging on thin cell sections is performed to obtain 
their nanoscale structures. The degree of nanoscale structural alterations of tumorigenic cells 
and anti-cancerous drug treated tumorigenic cells are quantified by using the recently developed 
inverse participation ratio (IPR) technique. Results show an increase in the degree of nanoscale 
fluctuations in tumorigenic cells relative to non-tumorigenic cells; then a nearly reverse of the 
degree of fluctuation of tumorigenic cells to that of non-tumorigenic cells, after the anti-
cancerous drugs treatment. These results support that the effect of anti-cancerous drugs in cancer 
treatment can be quantified by using the degree of nanoscale fluctuations of the cells via TEM 
imaging. Potential applications of the technique for cancer treatment are also discussed. 
Keywords: mesoscopic physics, inverse participation ratio, ovarian cancer, anti-cancerous drugs, tight binding 
model, structural disorder 
  
I.  Introduction: 
TEM imaging and probing nanoscale changes in cancer: TEM imaging is a method where we can probe 
~1 nm resolution within the sample, and this has been used for imaging of cells at the nanoscale to see the 
inner structures of the cells, in general, qualitatively. It has been established that the cancer progression is 
associated with the nanoscale structural alteration in a cell due to the rearrangements of the building blocks 
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of the cell such as DNA, RNA, and lipids. Therefore, TEM imaging is a good modality to probe cancerous 
changes in cells at the nanoscale level. Furthermore, the recently developed light wave localization 
technique, ‘inverse participation ratio’ (IPR), has shown success in quantifying the degree of structural 
changes in one parameter, known as the degree of structural disorder [1,2]. In particular, using the IPR 
method, a TEM image is used to construct a disordered 2D mass matrix, and from this we generate a 2D 
refractive index matrix. Optical waves are then solved for their eigenvalues and eigenfunctions using the 
refractive index matrix with closed boundary conditions. The light localization properties are measured 
by the average inverse participation ratio, <IPR>, and standard deviation of the IPR, σ(IPR), of the 
eigenfunctions of the light waves in these samples. It is shown that the degree of structural disorder is 
proportional to the <IPR> or σ(IPR) [3,4]. Therefore, the <IPR> can be used as a measure of the degree 
of nanoscale structural disorder, and to monitor structural change in cells under diseases condition. The 
IPR method is a very versatile approach.  The IPR method, using TEM imaging, has been recently 
generalized to study the structural changes in brain and colon cells in chronic alcoholism [5,6]. 
Furthermore, IPR method also extended to study the molecular specific (DNA, histone, etc.) structural 
changes in cells by using molecular specific fluorophores and confocal microscopy imaging [7,8]. 
 
Ovarian cancer:  
Ovarian cancer (OC) ranks the 5th in cancer related deaths among women and accounts for more deaths 
than any other cancer of female reproductive system. The American Cancer Society (ACS), estimated new 
cases of OC in USA in 2019 would be 22,530, whereas estimated deaths would be 14,000. Most OC cases 
are diagnosed at a very late stage, of which 51% are diagnosed as stage III and 29% are diagnosed as stage 
IV [9]. The exact cause that triggers OC is not clearly understood but there are several risk factors such as 
fertility therapy, late pregnancy, family history, hormone therapy after menopause etc. are associated with 
the development of OC. Metabolic alterations, suppression of tumor suppressor genes, oncogenic 
activations are also considered as triggering factors for OC initiation and progression of disease [10,11]. 
Although initially sensitive to chemotherapy treatment, however majority of the OC patients develop 
chemo resistant. 10 years survival rate for most patients of all stages of OC is ~30%. Development of 
chemoresistance, widespread disease during the time of diagnosis and tumor recurrence are the major 
challenges in the therapeutics of ovarian cancer [12]. 
In this study, we are focusing on analyzing the impact of novel anti-cancerous drug treatment in 
the tumor forming OC cell line in vitro. HSulf-1 knockdown OV202 cells are selected for this study for 
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their aggressive tumor forming ability and high proliferation rate [13,14]. This method of analysis is aimed 
to understand the effect of anti-cancerous drugs on cells in the early phases of treatment. Here we propose 
a novel approach to assess the impact of anti-cancerous drugs in cancerous cells by quantifying the degree 
of nanoscale structural disorder. 
 
II.  Method: 
Analytical formulation for the inverse participation ratio (IPR) technique from TEM images: TEM 
experiment has a resolution of ~1nm and can identify the nanoscale architectural alterations inside the 
cells which take place in normal cells when affected by cancer. These nano-alterations happen in the cells 
due to the rearrangement of the basic building blocks of the cells, such as DNA, RNA, lipids, 
macromolecules, etc. This results in mass density fluctuations in the cells. Using a thin slice of cell 
(~100nm), the mass density variations can be probed by TEM imaging. The IPR calculation is an efficient 
technique to measure and quantify the cancerous level of aggressiveness in a cell through its mass density 
fluctuations. A higher <IPR> or σ(IPR)  value indicates an increasing amount of the nanoscale mass 
density fluctuations in cells. The IPR technique is described in detail in earlier publications [1,2,4,5]. 
However, for a self-sufficient and completeness of this paper, we will describe the IPR technique in brief.    
The refractive index of a thin cell slice at a point n(x,y) with constant width dz has a voxel of 
volume dV=dxdydz which can be written as  n(x,y) = no+dn(x,y), where no is the average refractive index 
and dn(x,y) is the fluctuation of  refractive index at (x,y) indicated voxel. 
  TEM image intensity at any voxel point (x,y)  for a thin cell sample is represented as ITEM(x,y) and 
can be expressed as ITEM(x,y) = I0TEM + dITEM(x,y), where I0TEM  is the average pixel intensity and dITEM(x,y) 
is the fluctuation part of the pixel intensity. Here, the intensity fluctuation ITEM(x,y) is less than the average 
intensity I0TEM  and similarly, the fluctuation of refractive index dn(x,y) is less than the average refractive 
index n0. 
Optical parameter refractive index n(x,y) of the scattering substances is linearly proportional to the 
mass density of a biological cell for the thin samples [1-2]. Therefore, the intensity of a TEM images is 
linearly proportional to the mass, M, and refractive index of the voxel: 
                             
                                                           𝐼𝑇𝐸𝑀(𝑥, 𝑦)  ∝  𝑀(𝑥, 𝑦)  ∝  𝑛(𝑥, 𝑦)                                                             (1a)                                           
                                             𝐼0𝑇𝐸𝑀+ 𝑑𝐼𝑇𝐸𝑀(𝑥, 𝑦)  ∝  𝑀0 + 𝑑𝑀(𝑥, 𝑦)  ∝  𝑛0 + 𝑑𝑛(𝑥, 𝑦)                                                      (1b)                  
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From this, we can calculate optical potential of the voxel point as εi(x,y) to generate an optical lattice:  
                                                                 𝜀𝑖  = 𝑑𝑛(𝑥, 𝑦) 𝑛0⁄ ∝ 𝑑𝐼𝑇𝐸𝑀/𝐼0                                                                     (2)               
Knowing the optical potential at every point, an Anderson disorder tight binding model TBM Hamiltonian 
[15-17] can be generated as follows: 
                                          𝐻 = ∑ 𝜀𝑖|𝑖 >< 𝑗|𝑖 + 𝑡 ∑ (|𝑖 >< 𝑗| +⟨𝑖𝑗⟩ |𝑗 >< 𝑖|).                                                      (3) 
Where |i> and |j> are the eigenvectors of i-th and j-th lattice sites, εi(x,y) or simply εi, is the i-th lattice 
site optical potential energy and t is the overlap integral between sites i and j. The eigenfunctions (Ei’s) 
can now be generated from the above Hamiltonian by its diagonalization.  Finally, the average IPR value 
of the whole samples we can define as [1-4, 18,19]: 
                                                     < 𝐼𝑃𝑅 >𝑁  =
1
𝑁
∑ ∫ ∫ 𝐸𝑖
4(𝑥, 𝑦)𝑑𝑥𝑑𝑦,    
𝐿
0
𝐿
0
𝑁
𝑖=1                                                              (4)   
where Ei denotes the i-th eigenfunction of the Hamiltonian, N is the total number of potential points on the 
refractive index matrix (i.e., N=(L/dx)2). It has been shown that the average IPR value, <IPR>, is 
proportional to the degree of structural disorder Ld=dn×lc, where dn is the std of the all n(x,y) point and lc 
is the spatial correlation decay length of the n(x,y) over the sample [1,2]. Then,  
                                                                                                                                                          (5a)   
                                                                                                                                                          (5b)                                                             
Our statistical analysis involves calculating the average and standard deviation of the disorder strength of 
IPR values, i.e.  Ld values over the samples. Using this structural disorder strength <IPR> or (IPR) or 
Ld as a biomarker, we study the structural properties of the ovarian cancer cells with anti-cancerous drug 
treatments. In particular, we expect an increase in the structural disorder with the growth of cancer, and 
the reversibility of the structural disorder when the cancerous cells are treated with anti-cancerous drug, 
if the nanoscale structural disorder is a good cancer stage biomarker. 
III.  Sample Preparation and TEM imaging 
Ovarian normal and cancer cell lines: OV202 cell line is a low-passage primary ovarian cancer cell line 
established at the Mayo Clinic [13]. OV202 NTC (expressing HSulf-1) and Sh1 cells (HSulf-1 deficient) 
⟨𝐼𝑃𝑅⟩ ≡< 𝐼𝑃𝑅 >𝑒𝑛𝑠𝑒𝑚𝑏𝑙𝑒  ~ 𝐿𝑑 = ⅆ𝑛 × 𝑙𝑐 ,  
(𝐼𝑃𝑅) ≡ (𝐼𝑃𝑅)𝑒𝑛𝑠𝑒𝑚𝑏𝑙𝑒 ~ 𝐿𝑑 = ⅆ𝑛 × 𝑙𝑐  .   
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are developed by Dr. Shridhar’s group at Mayo Clinic and is described earlier elsewhere [14]. 
Subcutaneous injection of OV202 Sh1 cells resulted in tumor formation in nude mice, whereas HSulf-1 
expressing OV202 NTC cells did not form tumor [13]. Both cells were grown in minimum essential 
medium alpha 1X (Cellgro) supplemented with 20% fetal bovine serum (Biowest) and 1% penicillin-
streptomycin (Cellgro). All cells were grown in the presence of 1 μg/ml puromycin as a selection marker 
for the HSulf-1 shRNA cells were treated with 10 µl of AACOCF3 or MAFP (cPLA2 inhibitors; Cayman 
chemicals) for 24 hours. Following this treatment, cells were washed twice with PBS and then fixed in 
Trump’s fixative containing 4% formaldehyde and 1% glutaraldehyde in a phosphate buffer pH ~7.3, 
post-fixed in 1.0% OsO4, dehydrated with ethanol gradation, and transitioned into propylene oxide for 
infiltration and embedding into super epoxy resin.  
TEM imaging: Cell samples were fixed in Trump’s fixative (pH 7.2) at 4°C overnight, spun down and 
the supernatant removed. They were re-suspended in agarose which was cooled and solidified. The cells 
in agarose were then post-fixed in 1% OsO4, dehydrated through a graded series of ethanol and embedded 
in Spur resin. 100nm (or 0.1 μm) ultra-thin sections were mounted on 200-mesh copper grids, post-stained 
with lead citrate, and observed under a JEOL JEM-1400 transmission electron microscope at 80kV.  
 
 
IV.  Results and discussions:  
The TEM images of the ovarian cancer cells are obtained as described in the above section.  IPR analyses 
were performed for the samples on 165nm165nm TEM images. IPR averaging over the single cells, as 
well as over the different cells, were performed for ensemble averaging. As discussed above, the average 
<IPR> and σ(IPR) value for each TEM image was calculated and provides the degree of the structural 
disorder strength at a defined length scale. 
Figure 1(a)-(d) are the representative grayscale TEM images of a thin section (~100nm) of cell 
from the following ovarian cell lines: (i) non-tumorous NTC, (ii) tumorous Sh1, (iii) Sh1 treated with drug 
AACOCF3 (Sh1-AACOCF3), and (iv) Sh1 treated with drug MAPF (Sh1-MAFP). For each case study, 
~ 8-10 different cells  TEM images were taken from the cell line for averaging. Figure 1(a’)-(d’) are the 
corresponding (IPR) images of  Figure 1(a)-(d), at a length scale of  165nm and sample size of 
165165nm2. As can be seen from Figure 1, σ(IPR) images represent different intensities of disorder 
pattern in the cell line distinctly than conventional grayscale TEM images. In the IPR images, intensities 
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patterns of higher fluctuations in the cells are represented by the red spots and lower intensities with blue. 
In the figure, it can be seen that  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Variations of the standard deviation σ(IPR(L)) with the increase of length scale L, for cell lines non-tumorigenic 
(OV202 NTC); tumorigenic (OV202 Sh1); AACOCF3 treated tumorigenic Sh1 (Sh1-AACOCF3); and MAFP treated 
tumorous Sh1 (Sh1-MAFP). The ensemble averagins were performed over  TEM images of ~8-10 different cells.  It 
can be seen that the deviation between NTC and Sh1 started becoming prominent around the length scale ~100 nm. 
Interestingly, the drug treated Sh1 tumorigenic cells fluctuation degrees reverse to the non-tumorigenic cells. 
Fig 1: (a)-(d) are the representative TEM images and (a’)-(d’) are their respective IPR images from ovarian cells 
of  the following:  non-tumorous (OV202 NTC); tumorous (OV202 Sh1);  AACOCF3 treated tumorous Sh1, Sh-
AACOCF3;  and MAFP treated tumorous Sh1 Sh1-MAFP. IPR images are distinct from the TEM images. 
TEM 
Images 
IPR 
Images 
NTC  Sh1  Sh1-AACOCF3 Sh1-MAFP 
(a) (c) (b) (d) 
(a’) (b’) (d’) (c’) 
2µm 2µm 2µm 2µm 
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the increasing fluctuation or (IPR) value increases from the less proliferating NTC cells to highly 
proliferating Sh1cells, and decreasing of the fluctuations or (IPR) values decreases with the treatment of 
two different anti-cancerous drugs, AACOCF3 and MAFP. The drug effect can be distinctly visualized in 
the IPR images. 
Figure 2 shows length (L) dependent fluctuations with the sample size (L×L). We plotted, 
variations of the standard deviation σ(L) with the increase of sample lengths: L = 41,  82, 123, 165, 206, 
247, 288 nm. These lengths are for the cells from the following cell lines: non-tumorigenic (OV202 NTC); 
tumorigenic (OV202 Sh1); AACOCF3 treated tumorigenic Sh1 (Sh1-AACOCF3); and MAFP treated 
tumorous Sh1 (Sh1-MAFP).  As can be seen from the figure that the deviation in the degree of nano-
fluctuations between non-tumorigenic cells NCT and tumorigenic cells Sh1 started becoming prominent 
around the length scale ~100 nm. Interestingly, the degree of nano-fluctuations of anti-cancerous drugs 
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treated Sh1 tumorigenic cell reverse to that of the non-tumorigenic NTC cells. This confirms the efficacy 
of these two anti-cancerous drugs. 
Figure 3 presents the bar graphs of the standard deviation of calculated (IPR) or (Ld) value, of the ovarian 
cells at the fixed length scale 165nm. The variations are similar at lower sample length scales >165nm, 
however we have chosen 165nm to show a prominent difference. Statistically, the standard deviation is 
the more reliable marker than the average, as it only depends on the width of the distribution, irrespective 
to the mean position. The result shows the standard deviation of the degree of structural disorder (IPR) 
value increased by 70% from NTC to Sh1 cells. Furthermore, when Sh1 cells were treated with 2 different 
anti-cancerous drugs, AACOCF3 and MAFP, the (IPR) values decreased by around 60% for AACOCF3 
and 50% for MAFP, relative to the (IPR) value of the Sh1 tumorous cells. In particular, with the treatment 
of the anti-cancerous drug, the structural biomarker parameter (IPR) or Ld value decreased nearly back 
to the normal value. The normalcy detection of these anti-cancerous drug treated cancerous cells may 
require further investigations using different modalities. It has been earlier shown that AACOCF3 is a 
better anti-cancerous agent producing more anti-cancerous effects in OC cells compared to MAFP [20]. 
It can be seen in Fig. 3 that similar trend of bar graphs which show a reduction in the degree of structural 
disorder (IPR) value for AACOCF3 (60%) > MAFP(50%), consistent with the known qualities of the 
drugs, in this length scale. Hence, the quantitative analysis technique, called IPR, quantifies the nanoscale 
structural disorder (IPR) or Ld, as an important biomarker to study the structural alterations at nanoscale 
level and has potential to detect the effect of anti-cancerous drugs in carcinogenesis ovarian cancer.   
 
IV.  Conclusions 
The nanoscale mass-density fluctuations are quantified with the progression of carcinogenesis, as wells as 
the effects of two anti-cancerous drugs on non-tumor forming OV202NTC and tumor forming OV202Sh1 
cells are studied using TEM imaging and IPR technique. The nanoscale fluctuations are quantified by the 
std value of the IPR, (IPR), performed over an ensemble of samples. Results show an increase in the 
nanoscale fluctuations or (IPR) value from non-tumorous NTC to tumorous Sh1 cells. The (IPR) values 
for two different drugs treated tumorous cells, Sh1-AACOCF3 and Sh1-MAFP, have reduced value of the 
(IPR) from tumorous cells Sh1 and the reduced values are nearly same to the NTC non-tumorous cells. 
Earlier IPR analysis of a different cell line has verified the increase of nanoscale structural disorder with 
9 
 
the progression of cancer [1,2]. Based on the results presented, we investigate the potential applications 
of the IPR technique in measuring and quantifying the effectiveness of different anti-cancerous drugs on 
ovarian cancer treatment. This quantification of effectiveness of anti-cancerous drugs in ovarian cancer 
treatment could enhance better drugs treatment modalities at its earliest and helps to control the deadly 
ovarian cancer. Although this study is based on ovarian cancer, however, the technique can be applied to 
the varieties of cancers to assess the effectiveness of different anti-cancerous drugs in treatment. 
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